Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-3379 and Trametinib in Advanced NRAS Mutant or BRAF/NRAS Wildtype Melanoma
NCT03580382Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Jul 2018
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cdx-3379 in melanoma, sponsored by NYU Langone Health. Started Jul 2018; status: terminated.
02
Drugs
cdx-3379
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03580382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580382.